Author Archives: Omar Ford

SCA gets deeper into health care with proposed $2.9 billion BSN buy

By Omar Ford, Staff Writer Svenska Cellulosa AB (SCA) has entered into an agreement to acquire Luxembourg, Germany-based BSN Medical Ltd. for about $2.9 billion. The Stockholm, Sweden-based company is acquiring BSN from private equity firm EQT, and the transaction…

FacebookTwitterGoogle+Share

Femasys raises $40M in series C round, gains FDA approval for Fembloc IDE trial

By Omar Ford, Staff Writer Women’s health care startup Femasys Inc. has raised $40 million in a series C round. The Suwanee, Ga.-based company will use the funding to support the further development of Fembloc, a non-surgical, permanent contraception solution….

FacebookTwitterGoogle+Share

Hologic to sell profitable blood screening business to partner Grifols for $1.85B

By Stacy Lawrence, Contributing Writer Hologic Inc. is slated to sell its profitable blood screening business, which accounted for almost 20 percent of the Marlborough, Mass. company’s diagnostic revenues in fiscal 2016. The price is $1.85 billion in cash, which…

FacebookTwitterGoogle+Share

Novocure seeks to move TTFields therapy into pancreatic and ovarian cancer space

By Omar Ford, Staff Writer Novocure Ltd. is hoping to apply its Tumor Treating Fields (TTFields) therapy to both ovarian cancer and pancreatic cancer. During the St. Helier, Jersey Isle-based firm’s research and development day, it revealed top line results…

FacebookTwitterGoogle+Share

Insulet aims for its artificial pancreas to be on the U.S. market by late 2019

By Omar Ford, Staff Writer Insulet Corp. said Horizon, its artificial pancreas, could be on the U.S. market in late 2019. Horizon is the Billerica, Mass.-based firm’s first foray into continuous glucose monitoring-automated insulin delivery. If Insulet’s Horizon gains FDA…

FacebookTwitterGoogle+Share

TAVR key piece of Edwards’ 2017 outlook

By Omar Ford, Staff Writer Edwards Lifesciences Corp. said its 4Q16 revenue will come in at the low end of its $750 million to $790 million guidance range, but strong developments in the company’s product pipeline will give it a…

FacebookTwitterGoogle+Share

Abbott ready to bolt on Alere based on ‘damaging business developments’

By Amanda Pedersen, Senior Staff Writer After nearly 10 months of waffling on a $5.8 billion decision, Abbott Laboratories might have spotted an emergency exit from its contract to buy Alere Inc. “Alere is no longer the company Abbott agreed…

FacebookTwitterGoogle+Share

Australian firms hope for even faster approvals under proposed legislation

By Tamra Sami,  Staff Writer PERTH, Australia – Drug and device companies in Australia may soon be able to bring their products to market more quickly via a new priority review designation. Health Minister Susan Ley introduced legislation to Parliament…

FacebookTwitterGoogle+Share

Illumina spin-off launches massive study in search of cancer’s ‘Holy Grail’

By Amanda Pedersen, Senior Staff Writer A liquid biopsy company that spun out of Illumina Inc. in January to search for what it considers the holy grail of oncology – a blood test capable of detecting cancer at the earliest,…

FacebookTwitterGoogle+Share

Teleflex expands reach in interventional cardio with $1B Vascular Solutions buy

By Omar Ford, Staff Writer Wayne, Pa.-based, Teleflex Inc. is set to acquire Minneapolis-based Vascular Solutions Inc. in a transaction valued at about $1 billion. Teleflex’s offer of $56 per Vascular Solutions share represents a premium of 1.6 percent to…

FacebookTwitterGoogle+Share

Marketo